Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Perlegen -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (14)	1/3/2007 9:31:26 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 27

Perspectives on development of a combination pharmacogenomic diagnostic and drug product Pharmacogenomics October 2006, Vol. 7, No. 7, Pages 1045-1049 Mark McCamish, Raquel Izumi Perlegen Sciences, Inc., 2021 Stierlin Court, Mountain View, CA 94043, USA. Mark_McCamish@perlegen.com This perspective outlines the challenges to joint development of a predictive genetic diagnostic with a drug to enhance the efficacy or safety of therapy with the targeted drug. Joint development requires a discovery approach to identify the genetic marker(s), followed by a replication or validation process confirming the clinical utility of the genetic marker(s) in predicting response to the targeted drug. The promise of overcoming these hurdles is that combined use of the genetic diagnostic linked to the drug provides additional scientific information to assist the clinician in their choice of therapeutic interventions on a patient-by-patient basis. -------------- Haven't found a free copy online yet.